NTRA stock forecast
Our latest prediction for Natera Inc's stock price was made on the March 24, 2023 when the stock price was at 56.65$.
In the short term (2weeks), NTRA's stock price should underperform the market by -0.69%. During that period the price should oscillate between -6.42% and +3.19%.
In the medium term (3months), NTRA's stock price should outperform the market by 2.84%. During that period the price should oscillate between -25.33% and +15.77%.
Get email alertsCreate a solid portfolio with NTRA
About Natera Inc
Naterais a pioneer and global leader in cell-free DNA testing from a simple blood draw. The mission of the company is to change the management of disease worldwide with a focus on women's health, oncology, and organ health. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in San Carlos, California and Austin, Texas. It offers proprietary genetic testing services to inform obstetricians, transplant physicians, oncologists, and cancer researchers, including biopharmaceutical companies, and genetic laboratories through its cloud-based software platform.
At the moment the company generates 56M USD in revenues.
On its last earning announcement, the company reported a loss of -5.57$ per share.
The book value per share is -0.36$
Three months stock forecastMarch 24, 2023
Financials
| Revenue USD | Gross Margin | Operating Income | Operating Margin | Net Income | Earnings Per Share | Dividends | Payout Ratio | Shares | Book Value Per Share | Operating Cash Flow | Cap Spending | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 56M | 92.65% | -541M | -954.95% | -547M | -5.57 | - | - | 111M | -0.36 | - | - | - |